PUBLISHER: The Business Research Company | PRODUCT CODE: 1942732
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942732
Digital therapeutics (DTx) represent products that deliver evidence-based therapeutic treatments to patients through sophisticated software applications. These applications aim to prevent, manage, or treat various medical ailments or diseases.
The primary categories of digital therapeutics products encompass devices and software. Digital therapeutics devices offer interventions for the prevention, management, or treatment of diseases or medical disorders. This may involve sensors utilized to monitor medication usage and location data. The sales channels for digital therapeutics include both business-to-business (B2B) and business-to-consumer (B2C). Digital therapeutics find applications in both preventive and treatment or care-related contexts.
Tariffs are influencing the digital therapeutics market by increasing costs of imported wearable components, biosensors, electronic modules, and supporting hardware devices. Healthcare providers and technology firms in North America and Europe are most affected due to dependence on imported electronics, while Asia-Pacific faces cost pressure on device manufacturing. These tariffs are increasing development and deployment costs. However, they are also encouraging local device assembly, regional software innovation, and greater emphasis on scalable software-centric therapeutic solutions.
The digital therapeutics market research report is one of a series of new reports from The Business Research Company that provides digital therapeutics market statistics, including digital therapeutics industry global market size, regional shares, competitors with a digital therapeutics market share, detailed digital therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the digital therapeutics industry. This digital therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The digital therapeutics market size has grown exponentially in recent years. It will grow from $10.93 billion in 2025 to $14.02 billion in 2026 at a compound annual growth rate (CAGR) of 28.3%. The growth in the historic period can be attributed to growing smartphone penetration in healthcare, increased acceptance of digital health solutions, expansion of telemedicine services, early regulatory approvals for digital therapeutics, rising chronic disease burden.
The digital therapeutics market size is expected to see exponential growth in the next few years. It will grow to $37.82 billion in 2030 at a compound annual growth rate (CAGR) of 28.1%. The growth in the forecast period can be attributed to increasing reimbursement support for digital therapeutics, rising demand for personalized digital care, expansion of ai-driven treatment platforms, growing partnerships between healthcare providers and tech firms, increasing focus on preventive digital health. Major trends in the forecast period include increasing adoption of software-based therapeutic solutions, rising integration of wearable health devices, growing use of remote patient monitoring platforms, expansion of evidence-based digital care programs, enhanced focus on personalized treatment pathways.
The growing incidence of chronic diseases is poised to be a key driver propelling the expansion of the digital therapeutics market. Chronic diseases, characterized by long-lasting conditions requiring extended medical attention, significantly impact individuals' daily lives. Digital therapeutics, as software-based interventions, offer evidence-based therapeutic solutions to enhance the management of chronic diseases, providing patients with additional treatment options. Notably, data from the Centers for Disease Control and Prevention in July 2022 highlighted that six out of ten adults in the US are affected by chronic diseases, with four out of ten adults experiencing more than two chronic conditions such as heart disease, diabetes, and chronic lung diseases. This prevalence of chronic diseases contributes substantially to the growth trajectory of the digital therapeutics market.
Major companies operating in the digital therapeutics market are concentrating on technological advancements such as prescription-only digital behavioral therapy platforms to expand treatment access, strengthen patient engagement, and deliver clinically validated outcomes. A prescription-only digital behavioral therapy platform employs software-based interventions delivered through smartphones or tablets, incorporating evidence-based components such as cognitive behavioral therapy (CBT), remote monitoring, and interactive goal tracking, enabling scalable, drug-free disease management and personalized patient support. For example, in July 2023, Better Therapeutics, a U.S.-based prescription digital therapeutics company, introduced AspyreRx (formerly BT 001), a digital therapeutic designed for type 2 diabetes. The solution offers a 90-day self-guided program via a smartphone application, including weekly CBT sessions, individualized goal setting, and monitoring of blood glucose and lifestyle metrics, with clinical studies showing sustained reductions in HbA1c, weight improvements, and enhanced quality-of-life outcomes.
In July 2023, Big Health acquired Limbix for an undisclosed amount, aiming to expand its existing product portfolio. Big Health's product range includes Sleepio for insomnia and Daylight for anxiety, and with the acquisition of Limbix, it incorporates SparkRx and another teenage medication in development for anxiety. Limbix, a US-based provider of digital therapeutics, adds valuable assets to Big Health's offerings, enhancing its capabilities in providing a comprehensive suite of digital therapeutic solutions. This acquisition reflects the dynamic landscape of the digital therapeutics market, characterized by strategic moves to broaden product portfolios and meet the diverse needs of patients dealing with various health conditions.
Major companies operating in the digital therapeutics market are Omada Health Inc., WellDoc Inc., 2Morrow Inc., Propeller Health, Pear Therapeutics, Canary Health Inc., Noom Health Inc., Akili Interactive Labs, Better Therapeutics, Happify Health, Kaia Health, Medtronic plc, Teladoc Health Inc., Fitbit Health Solutions, EMulate Therapeutics, BigHealth, DarioHealth, IQVIA, JOGO Health, SilverCloud Health, Biofourmis Inc., Prosoma, Virta Health Corp., One Drop Inc., Lark Health, Xealth, CogniFit Ltd.
North America was the largest region in the digital therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the digital therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The digital therapeutics market consists of sales of products to treat a disease, manage a condition, and improve a health function. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Digital Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses digital therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for digital therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The digital therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.